openPR Logo
Press release

Insulin Biosimilars Market Size, Growth and SWOT Analysis by Key Players Boehringer Ingelheim, Pfizer Inc., Biocon, Merck & Co., Mylan N.V., Eli Lilly & Co., Wockhardt Limited, NOVO Nordisk A/S, Sanofi S.A

Insulin Biosimilars

Insulin Biosimilars

Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million people died due to the disease in 2012. Insulin biosimilar has the ability to increase access to treatment of diabetes mellitus among the patients while reducing treatment costs.

Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American Society For Metabolic And Bariatric Surgery report, obesity was a major independent risk factor for developing the disease, and more than 90% of type 2 diabetics population are overweight or obese due to growing adoption of unhealthy lifestyle. Insulin is distributed and manufactured by small number of multinational companies in emerging economies, beyond the established biosimilar manufactures, and a handful of small players are developing insulin manufacturing capacities based on modern biotechnological methods in turn, boosting growth of the insulin biosimilars market size.

Get The Holistic SAMPLE Of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/1750

Insulin Biosimilars Market – Dynamics

Increasing number of manufacturers are developing biosimilar insulin to provide clinical aid that are similar to current insulin analogs at the more affordable price. Moreover, the patents of several insulin manufacturing companies are soon expected to lose patent protection, For instance, LEVEMIR an Insulin detemir by Novo Nordisk is going to lose its patent rights in year 2019, which is influencing numerous pharmaceutical key manufacturers to develop alternatives to patents, referred as biosimilar. The low cost of biosimilar insulin for diabetes treatment and effectiveness is helping treat patients suffering from diabetes mellitus. Companies are also focusing on developing medical devices that allows for less painful and safe delivery of the biosimilar insulin treatment, which in turn, is boosting market growth. Government agencies are focusing on the endorsement of insulin biosimilar by funding research and development. Furthermore, rising geriatric population across the globe and increasing demand for rapid-acting insulin analogues is boosting growth of the insulin biosimilar market. For instance, according to a consensus report published in 2012 American Diabetes Association, showed over 25% of the U.S. population aged ≥65 years suffered from diabetes.

However, critical regulatory requirements for approval of insulin biosimilar products besides strong opposition from branded manufactures regarding patent rights, high cost of production, manufacturing complexities, and various safety concerns associated with changes in drug formulations pose as factors hampering growth of the insulin biosimilars market.

Insulin Biosimilars Market – Regional Insights

On the basis of region, the global insulin biosimilars market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America leads the global insulin biosimilar market, owing to rising geriatric population and high prevalence of diabetes-related disorders in the region. Moreover, government support for diabetes-free states is accelerating growth of the insulin biosimilar market in North America. For instance, Centers for Disease Control and Prevention (CDC) runs a National Diabetes Prevention Program in various U.S states.

The market in Europe accounts for the second-leading share in the global market, mainly due to increasing number of primary approvals for biosimilar insulin. For example, European Commission (EC) approved Mylan and Biocon’s biosimilar insulin—Glargine—for treating diabetes on March 27, 2018. Asia Pacific market is expected to gain significant traction over the forecast period due to increasing government support, improving healthcare conditions and growing diabetes incidence in the region. For instance, 2011 World Health Organization report shows that diabetes deaths will double between 20011 and 2030.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1750

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Insulin Biosimilars Market Size, Growth and SWOT Analysis by Key Players Boehringer Ingelheim, Pfizer Inc., Biocon, Merck & Co., Mylan N.V., Eli Lilly & Co., Wockhardt Limited, NOVO Nordisk A/S, Sanofi S.A here

News-ID: 1332575 • Views:

More Releases from Coherent Market Insights Biotechnology

Wound Care Biologics Market 2026: Global Industry Insights And Growth Analysis By Top Players - Smith & Nephew Plc., Organogenesis, Integra Lifesciences Holdings Corporation
Wound Care Biologics Market 2026: Global Industry Insights And Growth Analysis B …
Wound care biologic products facilitates in innate repair mechanisms, and involves the use of active biological agents such as animal and plant-derived active biomolecules, which exhibit antioxidant, antimicrobial, or anti-inflammatory properties. Wound care biologic dressings are increasingly being used in post surgeries and severe trauma cases as they provide moist healing environment aiding heat loss, protein and electrolyte loss for faster healing, and prevent bacterial contamination. Biologic skin substitute products
Bone Marrow Transplant Market 2018 With Major Key Players STEMCELL Technologies, Merck Millipore Corporation, Sanofi-Aventis , AllCells, ReachBio
Bone Marrow Transplant Market 2018 With Major Key Players STEMCELL Technologies, …
Bone marrow transplant is a medical procedure to replace bone marrow damaged or destroyed by disease, infection, or chemotherapy. Bone marrow transplant procedure involves transplanting blood stem cells that travel to the bone marrow where they produce new blood cells and promote growth of new marrow. Bone marrow is the spongy, fatty tissue inside human bones, which creates the different parts of blood such as red blood cells that carry
Targeted Cancer Therapies Market Future and Technological Advancement To 2026 With Key Vendors Abbott Laboratories, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, AstraZeneca PLC, OncoGenex Pharmaceuticals Inc., Pfizer
Targeted Cancer Therapies Market Future and Technological Advancement To 2026 Wi …
Targeted cancer therapies are drugs which block the growth and proliferation of cancer by interfering with specific molecules such as DNA or proteins, which are involved in the growth or expansion of cancerous cells. Targeted cancer therapies differ in several ways from standard chemotherapy. Standard chemotherapy act on all rapidly dividing cancerous cells as well as normal cells, while targeted cancer therapies act on specific molecular targets that are associated
Platelet Rich Plasma Market And Key Players Harvest Technologies Corporation, Biomet, Arthrex, Arteriocyte Medical systems, Dr. PRP America LLC, EmCyte Corporation, Regen Lab Sa
Platelet Rich Plasma Market And Key Players Harvest Technologies Corporation, Bi …
CMI released a new market study on 2017-2025 Platelet Rich Plasma Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates

All 5 Releases


More Releases for Insulin

Advancing Insulin Delivery Systems boost the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032. Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary This insightful
Advancing Insulin Delivery Systems boost the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032. Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary This insightful
Advancing Insulin Delivery Systems boost the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032. Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary This insightful
Insulin Pumps Market Share, Trends and Growth Analysis By Type (Traditional Insu …
Insulin Pumps Market is expected to register a CAGR of 15.5% and acquire the market value of USD 11.5 Billion by 2028 during forecast period 2023-2032. Insulin pumps are discreet, electronic medical devices that can be tucked beneath clothing or fastened to a belt. In order to regulate the rise in blood glucose levels, the pump is used to deliver controlled quantities of insulin within the body at regular intervals
Insulin Patch Pumps Market Report 2018: Segmentation by Insulin Type (Bolus Insu …
Global Insulin Patch Pumps market research report provides company profile for Roche Holding AG, Cellnovo Group SA, Spring Health Solution Ltd., Debiotech, CeQur SA, Valeritas, Becton Dickenson & Company, Insulet Corporation, Johnson & Johnson, Medtrum Technologies Inc. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue,
Insulin pump Market Explore Future Growth 2018-2026 by Global Type-Traditional i …
Insulin pump is a portable device attached to the body that continuously delivers preset amounts of short or rapid acting insulin in the body to control diabetes. Insulin therapy is required in type 1 diabetes and sometime in type 2 diabetes. It serves as an effective alternative to insulin injections. Furthermore, insulin pump delivers the insulin according to the need of body as basal rate, where small amount of insulin